Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Predictive and Prognostic Biomarkers of Human Cancer in Italy
share announcement

Predictive and Prognostic Biomarkers of Human Cancer in Italy

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 5995

Special Issue Editors

Dr. Manuel Scimeca

E-Mail Website
Guest Editor
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy
Interests: environmental pollution; oncology; cardiovascular diseases; electron microscopy; histology
Special Issues, Collections and Topics in MDPI journals
Dr. Rita Bonfiglio

E-Mail Website
Guest Editor
Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy
Interests: oncology; breast cancer; molecular pathology; mouse models; theragnostics
Special Issues, Collections and Topics in MDPI journals
Dr. Manuela Montanaro

E-Mail Website
Guest Editor
Department of Biomedicine and Prevention - Tor Vergata, University of Rome Tor Vergata, 00133 Rome, Italy
Interests: cancer biomarkers; pathology; atherosclerosis; biotechnology; histopathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The identification of novel predictive and prognostic biomarkers capable to early detect human cancers, as well as to support clinicians in choosing the best therapeutic protocols, is considered one of the main challenges of the Italian scientific community. In this scenario, multidisciplinary cooperation among different biomedical fields, such as imaging diagnostics, molecular imaging, clinical laboratory analysis, pathology, and artificial intelligence, could represent an ideal scientific platform for identifying novel promising biomarkers. This innovative approach may significantly improve the armamentarium available for Italian clinicians and thus ameliorate the management of patients affected by human cancers.

Starting from these considerations, the aim of this Special Issue is to publish the latest discoveries and bring together researchers and clinicians working in the identification of new prognostic and predictive biomarkers of human cancer in Italy. Topics will include (but are not limited to) the following:

  • Identification of prognostic and predictive biomarkers of human cancers;
  • Early imaging markers for human cancers;
  • In situ expression of novel prognostic and predictive biomarkers;
  • New advances in circulating biomarkers of human cancers;
  • Identification and development of new molecules for theragnostic approaches in human cancer;
  • Artificial intelligence and machine learning as support clinical investigations concerning new biomarkers for human cancer.

Dr. Manuel Scimeca
Dr. Rita Bonfiglio 
Dr. Manuela Montanaro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prognostic biomarkers
  • predictive biomarkers
  • cancer
  • pathology
  • applied medical technologies
  • diagnostic imaging

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 9697 KiB  
Article
The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis
by Manuel Scimeca, Manuela Montanaro, Rita Bonfiglio, Lucia Anemona, Enrico Finazzi Agrò, Anastasios D. Asimakopoulos, Roberto Bei, Vittorio Manzari, Nicoletta Urbano, Erica Giacobbi, Francesca Servadei, Elena Bonanno, Orazio Schillaci and Alessandro Mauriello
Diagnostics 2022, 12(4), 800; https://doi.org/10.3390/diagnostics12040800 - 24 Mar 2022
Cited by 3 | Viewed by 1876
Abstract
The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort [...] Read more.
The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient’s quality of life. Full article
(This article belongs to the Special Issue Predictive and Prognostic Biomarkers of Human Cancer in Italy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 283 KiB  
Review
Unraveling the Puzzle: Oocyte Maturation Abnormalities (OMAS)
by Safak Hatirnaz, Ebru Hatirnaz, Samettin Çelik, Canan Soyer Çalışkan, Andrea Tinelli, Antonio Malvasi, Radmila Sparic, Domenico Baldini, Michael Stark and Michael H. Dahan
Diagnostics 2022, 12(10), 2501; https://doi.org/10.3390/diagnostics12102501 - 15 Oct 2022
Cited by 4 | Viewed by 2006
Abstract
Oocyte maturation abnormalities (OMAS) are a poorly understood area of reproductive medicine. Much remains to be understood about how OMAS occur. However, current knowledge has provided some insight into the mechanistic and genetic origins of this syndrome. In this study, current classifications of [...] Read more.
Oocyte maturation abnormalities (OMAS) are a poorly understood area of reproductive medicine. Much remains to be understood about how OMAS occur. However, current knowledge has provided some insight into the mechanistic and genetic origins of this syndrome. In this study, current classifications of OMAS syndromes are discussed and areas of inadequacy are highlighted. We explain why empty follicle syndrome, dysmorphic oocytes, some types of premature ovarian insufficiency and resistant ovary syndrome can cause OMAS. We discuss live births in different types of OMAS and when subjects can be offered treatment with autologous oocytes. As such, we present this review of the mechanism and understanding of OMAS to better lead the clinician in understanding this difficult-to-treat diagnosis. Full article
(This article belongs to the Special Issue Predictive and Prognostic Biomarkers of Human Cancer in Italy)
15 pages, 678 KiB  
Review
Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches
by Silvia Grassilli, Valeria Bertagnolo and Federica Brugnoli
Diagnostics 2022, 12(9), 2139; https://doi.org/10.3390/diagnostics12092139 - 02 Sep 2022
Cited by 5 | Viewed by 1730
Abstract
The miR-29 family comprises miR-29a, miR-29b, and miR-29c, and these molecules play crucial and partially overlapped functions in solid tumors, in which the different isoforms are variously de-regulated and mainly correlated with tumor suppression. miR-29b is the most expressed family member in cancer, [...] Read more.
The miR-29 family comprises miR-29a, miR-29b, and miR-29c, and these molecules play crucial and partially overlapped functions in solid tumors, in which the different isoforms are variously de-regulated and mainly correlated with tumor suppression. miR-29b is the most expressed family member in cancer, in which it is involved in regulating gene expression at both transcriptional and post-transcriptional levels. This review focuses on the role of miR-29b in breast cancer, in which it plays a controversial role as tumor suppressor or onco-miRNA. Here we have highlighted the dual effect of miR-29b on breast tumor features, which depend on the prevailing function of this miRNA, on the mature miR-29b evaluated, and on the breast tumor characteristics. Remarkably, the analyzed miR-29b form emerged as a crucial element in the results obtained by various research groups, as the most abundant miR-29b-3p and the less expressed miR-29b1-5p seem to play distinct roles in breast tumors with different phenotypes. Of particular interest are the data showing that miR-29b1-5p counteracts cell proliferation and migration and reduces stemness in breast tumor cells with a triple negative phenotype. Even if further studies are required to define exactly the role of each miR-29b, our review highlights its possible implication in phenotype-specific management of breast tumors. Full article
(This article belongs to the Special Issue Predictive and Prognostic Biomarkers of Human Cancer in Italy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop